Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0007 USD
Change Today -0.0001 / -12.50%
Volume 25.6M
BIEL On Other Exchanges
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

bioelectronics corp (BIEL) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/1/14 - $0.0022
52 Week Low
05/6/15 - $0.0004
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOELECTRONICS CORP (BIEL)

Related News

No related news articles were found.

bioelectronics corp (BIEL) Related Businessweek News

No Related Businessweek News Found

bioelectronics corp (BIEL) Details

BioElectronics Corporation develops, manufactures, and markets drug–free, topical pain medical devices. Its products comprise ActiPatch therapy for over-the-counter treatment of back pain and other musculoskeletal complaints; Allay menstrual cycle pain therapy; RecoveryRx for chronic and post-operative wound care; and HealFast therapy, a drug-free therapy for healing of muscle and tendon injuries, sores, and incision in horses, cats, and dogs. The company markets and sells its products under the ActiPatch, Allay, and RecoveryRx brand names through distributors primarily in Korea, Singapore, Malaysia, Canada, Columbia, Scandinavia, Saudi Arabia, the Balkans, Australia, China, and South America. BioElectronics Corporation was founded in 2000 and is based in Frederick, Maryland.

bioelectronics corp (BIEL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioelectronics corp (BIEL) Key Developments

BioElectronics Corporation Expands Medical and OTC Distribution in Partnership with Medikon

BioElectronics Corporation has signed Medikon as the distributor for RecoveryRx Therapy for post-operative and chronic wound care, ActiPatch Musculoskeletal Therapy, Allay Menstrual Pain Therapy and Smart Insole in Turkey.

BioElectronics Corporation, USA Announces B. Braun as UK Distributor for Pain Device in Orthopaedics

BioElectronics Corporation, USA, announced that B. Braun Medical Ltd. is the exclusive UK distributor of the BioElectronics' RecoveryRx® pain device in orthopaedics and trauma. RecoveryRx® is a micro medical device that treats acute and chronic musculoskeletal pain and decreases oedema. RecoveryRx® will be introduced in the B. Braun enhanced recovery surgical programs, particularly hip and knee joint replacement and spine surgery, as well as use in orthopaedic trauma. RecoveryRx® in joint replacements will enable better prehabilitation in preparation for surgery and provide improved acute post-operative pain relief, earlier mobilization, faster less painful rehabilitation and better restoration of function.

Bioelectronics Corporation Announces Interim Results of Placebo Controlled Trial on Osteoarthritis of the Knee Using ActiPatch(R) Therapy

BioElectronics Corporation announced more detail on the interim results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee (knee pain) using ActiPatch(R) Therapy. Arthritis is the major cause of disability in the US affecting 52.5 million adults. Osteoarthritis of the knee is the most common musculoskeletal pain and disability condition. Therefore it are extremely pleased by the results of Dr. Gianluca Bagnato's clinical study. ActiPatch(R) Musculoskeletal Pain Therapy devices are readily available, over-the-counter outside of the US, for approximately $30.00, or $0.04 per hour of therapy. The specific four weeks of ActiPatch(R) Therapy showed the following: Patients treated with ActiPatch(R) Therapy showed a statistically significant improvement in visual analogue pain scores (VAS) (p<0.005) and WOMAC pain scores (p<0.001) at 4 weeks compared to baseline. Patients treated with ActiPatch(R) Therapy assessed for function and disability showed statistically significant improvement for WOMAC function (p<0.002) and WOMAC stiffness (p<0.02) at 4 weeks compared to baseline. Patients treated with ActiPatch(R) Therapy also demonstrated statistically significant (p<0.04) improved physical and mental health as assessed by the SF-36 (36-item Medical Outcomes Study Short-Form 36 version 2) at 4 weeks compared to baseline. No statistically significant results were recorded in the placebo group.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIEL:US $0.00 USD -0.0001

BIEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIEL.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOELECTRONICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at